Clinical trial
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination…
NCT00000625 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000625 |
|---|---|
| Title | A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3 |
| Official title | A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3 |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Bristol-Myers Squibb Industry Glaxo Wellcome |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Zidovudine, Zalcitabine, Didanosine |
| Enrollment | 2,100 |
| Completion | Nov 1, 1995 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 2, 2021 |
| Countries | Puerto Rico, Tanzania, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: